Enasidenib Clinical Trials
12 recruitingDrug
Phase 210Phase 14
Showing 1–12 of 12 trials
Recruiting
Phase 2
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Acute Myeloid LeukemiaMyelodysplastic SyndromeAcute Myeloid Leukemia Post Cytotoxic Therapy+2 more
National Cancer Institute (NCI)2,000 enrolled346 locationsNCT05564390
Recruiting
Phase 2
Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors
Metastatic ChondrosarcomaLocally Advanced ChondrosarcomaMetastatic Sinonasal Adenocarcinoma+7 more
National Cancer Institute (NCI)40 enrolled1 locationNCT06176989
Recruiting
Phase 2
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Acute Myeloid Leukemia
National Cancer Institute (NCI)93 enrolled122 locationsNCT06672146
Recruiting
Phase 2
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
Myelodysplastic Syndrome
National Cancer Institute (NCI)54 enrolled139 locationsNCT06577441
Recruiting
Phase 2
A Study of Enasidenib in People With T-Cell Lymphoma
T-cell Lymphoma
Memorial Sloan Kettering Cancer Center25 enrolled8 locationsNCT06756308
Recruiting
Phase 1
A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia (AML)
Memorial Sloan Kettering Cancer Center18 enrolled7 locationsNCT05756777
Recruiting
Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
Acute Myeloid LeukemiaChronic Myelomonocytic LeukemiaRecurrent High Risk Myelodysplastic Syndrome+4 more
M.D. Anderson Cancer Center63 enrolled3 locationsNCT03383575
Recruiting
Phase 2
Enasidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH2A Decentralized Trial
Clonal Cytopenia of Undetermined SignificanceCCUS Clonal Cytopenia of Undetermined Significance
Washington University School of Medicine15 enrolled1 locationNCT06240754
Recruiting
Phase 1Phase 2
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
Pediatric Cancer
Gustave Roussy, Cancer Campus, Grand Paris472 enrolled21 locationsNCT02813135
Recruiting
Phase 1
Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission
Acute Myeloid Leukemia
M.D. Anderson Cancer Center125 enrolled1 locationNCT05010772
Recruiting
Phase 1Phase 2
Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Acute Myeloid LeukemiaRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center84 enrolled1 locationNCT04774393
Recruiting
Phase 2
IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)
Acute Myeloid Leukemia
Alice Mims125 enrolled1 locationNCT05401097